Sphingosine-1-phosphate receptor modulator (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sphingosine-1-phosphate receptor modulator" in English language version.

refsWebsite

Global rank English rank

17nih.gov

4^th place

12doi.org

2^nd place

1semanticscholar.org

11^th place

8^th place

doi.org

"Department of Error". Lancet. 398 (10306): 1132. September 2021. doi:10.1016/S0140-6736(21)02050-X. PMID 34563294.
Dyckman AJ (July 2017). "Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P₁) Agonists and Future Perspectives". Journal of Medicinal Chemistry. 60 (13): 5267–5289. doi:10.1021/acs.jmedchem.6b01575. PMID 28291340.
Park SJ, Im DS (January 2017). "Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery". Biomolecules & Therapeutics. 25 (1): 80–90. doi:10.4062/biomolther.2016.160. PMC 5207465. PMID 28035084.
Adachi K, Chiba K (September 2007). "FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology". Perspectives in Medicinal Chemistry. 1: 11–23. doi:10.1177/1177391X0700100002. PMC 2754916. PMID 19812733.
Pelletier D, Hafler DA (January 2012). "Fingolimod for multiple sclerosis". The New England Journal of Medicine. 366 (4): 339–347. doi:10.1056/NEJMct1101691. PMID 22276823.
Mao-Draayer Y, Sarazin J, Fox D, Schiopu E (February 2017). "The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases". Clinical Immunology. 175: 10–15. doi:10.1016/j.clim.2016.11.008. PMC 5315594. PMID 27890706.
Demont EH, Andrews BI, Bit RA, Campbell CA, Cooke JW, Deeks N, et al. (June 2011). "Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate". ACS Medicinal Chemistry Letters. 2 (6): 444–449. doi:10.1021/ml2000214. PMC 4018134. PMID 24900328.
Yeung BK (August 2011). "Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B". Current Opinion in Chemical Biology. 15 (4): 523–528. doi:10.1016/j.cbpa.2011.05.019. PMID 21684798.
Gilmore JL, Sheppeck JE, Watterson SH, Haque L, Mukhopadhyay P, Tebben AJ, et al. (July 2016). "Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)". Journal of Medicinal Chemistry. 59 (13): 6248–6264. doi:10.1021/acs.jmedchem.6b00373. PMID 27309907.
Adachi K, Kohara T, Nakao N, Arita M, Chiba K, Mishina T, et al. (April 1995). "Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720". Bioorganic & Medicinal Chemistry Letters. 5 (8): 853–856. doi:10.1016/0960-894X(95)00127-F.
Subei AM, Cohen JA (July 2015). "Sphingosine 1-phosphate receptor modulators in multiple sclerosis". CNS Drugs. 29 (7): 565–575. doi:10.1007/s40263-015-0261-z. PMC 4554772. PMID 26239599.
Liu Z, Liao Q, Wen H, Zhang Y (June 2021). "Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis". Autoimmunity Reviews. 20 (6): 102826. doi:10.1016/j.autrev.2021.102826. PMID 33878488. S2CID 233325057.

nih.gov

pubmed.ncbi.nlm.nih.gov

"Department of Error". Lancet. 398 (10306): 1132. September 2021. doi:10.1016/S0140-6736(21)02050-X. PMID 34563294.
Dyckman AJ (July 2017). "Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P₁) Agonists and Future Perspectives". Journal of Medicinal Chemistry. 60 (13): 5267–5289. doi:10.1021/acs.jmedchem.6b01575. PMID 28291340.
Park SJ, Im DS (January 2017). "Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery". Biomolecules & Therapeutics. 25 (1): 80–90. doi:10.4062/biomolther.2016.160. PMC 5207465. PMID 28035084.
Adachi K, Chiba K (September 2007). "FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology". Perspectives in Medicinal Chemistry. 1: 11–23. doi:10.1177/1177391X0700100002. PMC 2754916. PMID 19812733.
Pelletier D, Hafler DA (January 2012). "Fingolimod for multiple sclerosis". The New England Journal of Medicine. 366 (4): 339–347. doi:10.1056/NEJMct1101691. PMID 22276823.
Mao-Draayer Y, Sarazin J, Fox D, Schiopu E (February 2017). "The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases". Clinical Immunology. 175: 10–15. doi:10.1016/j.clim.2016.11.008. PMC 5315594. PMID 27890706.
Demont EH, Andrews BI, Bit RA, Campbell CA, Cooke JW, Deeks N, et al. (June 2011). "Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate". ACS Medicinal Chemistry Letters. 2 (6): 444–449. doi:10.1021/ml2000214. PMC 4018134. PMID 24900328.
Yeung BK (August 2011). "Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B". Current Opinion in Chemical Biology. 15 (4): 523–528. doi:10.1016/j.cbpa.2011.05.019. PMID 21684798.
Gilmore JL, Sheppeck JE, Watterson SH, Haque L, Mukhopadhyay P, Tebben AJ, et al. (July 2016). "Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)". Journal of Medicinal Chemistry. 59 (13): 6248–6264. doi:10.1021/acs.jmedchem.6b00373. PMID 27309907.
Subei AM, Cohen JA (July 2015). "Sphingosine 1-phosphate receptor modulators in multiple sclerosis". CNS Drugs. 29 (7): 565–575. doi:10.1007/s40263-015-0261-z. PMC 4554772. PMID 26239599.
Liu Z, Liao Q, Wen H, Zhang Y (June 2021). "Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis". Autoimmunity Reviews. 20 (6): 102826. doi:10.1016/j.autrev.2021.102826. PMID 33878488. S2CID 233325057.

ncbi.nlm.nih.gov

Park SJ, Im DS (January 2017). "Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery". Biomolecules & Therapeutics. 25 (1): 80–90. doi:10.4062/biomolther.2016.160. PMC 5207465. PMID 28035084.
Adachi K, Chiba K (September 2007). "FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology". Perspectives in Medicinal Chemistry. 1: 11–23. doi:10.1177/1177391X0700100002. PMC 2754916. PMID 19812733.
Mao-Draayer Y, Sarazin J, Fox D, Schiopu E (February 2017). "The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases". Clinical Immunology. 175: 10–15. doi:10.1016/j.clim.2016.11.008. PMC 5315594. PMID 27890706.
Demont EH, Andrews BI, Bit RA, Campbell CA, Cooke JW, Deeks N, et al. (June 2011). "Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate". ACS Medicinal Chemistry Letters. 2 (6): 444–449. doi:10.1021/ml2000214. PMC 4018134. PMID 24900328.
Subei AM, Cohen JA (July 2015). "Sphingosine 1-phosphate receptor modulators in multiple sclerosis". CNS Drugs. 29 (7): 565–575. doi:10.1007/s40263-015-0261-z. PMC 4554772. PMID 26239599.

ninds.nih.gov

"Multiple Sclerosis Information Page | National Institute of Neurological Disorders and Stroke". www.ninds.nih.gov. Retrieved 2017-10-02.

semanticscholar.org

api.semanticscholar.org

Liu Z, Liao Q, Wen H, Zhang Y (June 2021). "Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis". Autoimmunity Reviews. 20 (6): 102826. doi:10.1016/j.autrev.2021.102826. PMID 33878488. S2CID 233325057.